CO6361921A2 - 3-aminociclopentancarboxamidas - Google Patents
3-aminociclopentancarboxamidasInfo
- Publication number
- CO6361921A2 CO6361921A2 CO11064157A CO11064157A CO6361921A2 CO 6361921 A2 CO6361921 A2 CO 6361921A2 CO 11064157 A CO11064157 A CO 11064157A CO 11064157 A CO11064157 A CO 11064157A CO 6361921 A2 CO6361921 A2 CO 6361921A2
- Authority
- CO
- Colombia
- Prior art keywords
- activity
- aminociclopentancarboxamidas
- ccr2
- ccr5
- modulates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Abstract
Se provee un compuesto de la Fórmula I(a) o I(b):o una sal de éste farmacéuticamente aceptable los cuales modulan la actividad de receptores de quimiocina, tales como CCR2 y CCR5. Los compuestos se pueden usar, por ejemplo, para tratar enfermedades asociadas con la expresión o actividad del receptor de quimiocina, en donde varios sustituyentes se definen en la presente.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11805308P | 2008-11-26 | 2008-11-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6361921A2 true CO6361921A2 (es) | 2012-01-20 |
Family
ID=41693100
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO11064157A CO6361921A2 (es) | 2008-11-26 | 2011-05-24 | 3-aminociclopentancarboxamidas |
Country Status (39)
Country | Link |
---|---|
US (2) | US8293903B2 (es) |
EP (1) | EP2370442B9 (es) |
JP (1) | JP5108153B2 (es) |
KR (1) | KR101374412B1 (es) |
CN (1) | CN102227429B (es) |
AP (1) | AP3113A (es) |
AU (1) | AU2009321221B2 (es) |
BR (1) | BRPI0920936A2 (es) |
CA (1) | CA2743030C (es) |
CL (1) | CL2011001223A1 (es) |
CO (1) | CO6361921A2 (es) |
CR (1) | CR20110275A (es) |
CU (1) | CU24022B1 (es) |
CY (1) | CY1114020T1 (es) |
DK (1) | DK2370442T5 (es) |
DO (1) | DOP2011000154A (es) |
EA (1) | EA020470B1 (es) |
EC (1) | ECSP11011081A (es) |
ES (1) | ES2415430T3 (es) |
GE (1) | GEP20146064B (es) |
HK (1) | HK1161261A1 (es) |
HR (1) | HRP20130409T2 (es) |
IL (1) | IL212732A (es) |
MA (1) | MA32834B1 (es) |
ME (1) | ME01144B (es) |
MX (1) | MX2011005526A (es) |
MY (1) | MY152557A (es) |
NI (1) | NI201100102A (es) |
NZ (1) | NZ592919A (es) |
PE (1) | PE20110831A1 (es) |
PL (1) | PL2370442T3 (es) |
PT (1) | PT2370442E (es) |
RS (2) | RS52810B9 (es) |
SI (1) | SI2370442T1 (es) |
SV (1) | SV2011003923A (es) |
TN (1) | TN2011000254A1 (es) |
UA (1) | UA99978C2 (es) |
WO (1) | WO2010061329A1 (es) |
ZA (1) | ZA201104069B (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010061329A1 (en) * | 2008-11-26 | 2010-06-03 | Pfizer Inc. | 3-aminocyclopentanecarboxamides as chemokine receptor modulators |
KR101303963B1 (ko) * | 2011-04-08 | 2013-09-05 | 재단법인 경기과학기술진흥원 | (1r,2r,3r)-3-아미노사이클로펜탄-1,2-디올을 포함하는 항알러지용 조성물 |
KR102456088B1 (ko) | 2014-04-04 | 2022-10-19 | 델 마 파마슈티컬스 | 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체 |
JP2016029038A (ja) * | 2014-07-17 | 2016-03-03 | 参天製薬株式会社 | 加齢黄斑変性の予防または治療剤 |
JOP20190040A1 (ar) * | 2016-09-14 | 2019-03-10 | Novartis Ag | توليفة من ناهضات fxr |
WO2019215268A1 (en) * | 2018-05-11 | 2019-11-14 | Astrazeneca Ab | Cyclopentane compounds |
JP7412034B1 (ja) | 2022-11-02 | 2024-01-12 | 鈴木製機株式会社 | 搬送システム |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU693143B2 (en) | 1993-12-06 | 1998-06-25 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using the same |
US5510332A (en) | 1994-07-07 | 1996-04-23 | Texas Biotechnology Corporation | Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor |
CA2193508A1 (en) | 1994-07-11 | 1996-01-25 | Eugene D. Thorsett | Inhibitors of leukocyte adhesion |
US5462208A (en) | 1994-08-01 | 1995-10-31 | The Procter & Gamble Company | Two-phase dispensing systems utilizing bellows pumps |
US5811391A (en) | 1994-08-25 | 1998-09-22 | Cytel Corporation | Cyclic CS-1 peptidomimetics, compositions and methods of using same |
GB9524630D0 (en) | 1994-12-24 | 1996-01-31 | Zeneca Ltd | Chemical compounds |
US6306840B1 (en) | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
AU5259296A (en) | 1995-04-07 | 1996-10-23 | Warner-Lambert Company | Flavones and coumarins as agents for the treatment of athero sclerosis |
US5704960A (en) | 1995-12-20 | 1998-01-06 | Corning, Inc. | Method of forming an optical fiber for reduced polarization effects in amplifiers |
GB9603741D0 (en) | 1996-02-22 | 1996-04-24 | Lin Mei | Treatment of water by electrolysis |
AU729415B2 (en) | 1996-07-12 | 2001-02-01 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
WO1998042656A1 (en) | 1997-03-21 | 1998-10-01 | Cytel Corporation | Novel compounds |
JP2002501537A (ja) | 1997-05-29 | 2002-01-15 | メルク エンド カンパニー インコーポレーテッド | 細胞接着阻害薬としてのスルホンアミド類 |
AU726585B2 (en) | 1997-05-29 | 2000-11-09 | Merck & Co., Inc. | Biarylalkanoic acids as cell adhesion inhibitors |
EP1001764A4 (en) | 1997-05-29 | 2005-08-24 | Merck & Co Inc | Heterocyclic amides as cell adhesion inhibitors |
WO1998054207A1 (en) | 1997-05-30 | 1998-12-03 | Celltech Therapeutics Limited | Anti-inflammatory tyrosine derivatives |
PT991619E (pt) | 1997-06-23 | 2004-02-27 | Upjohn Co | Inibidores da adesao celular mediada pela alfa4beta1 |
US6312689B1 (en) | 1998-07-23 | 2001-11-06 | Millennium Pharmaceuticals, Inc. | Anti-CCR2 antibodies and methods of use therefor |
JO2479B1 (en) * | 2002-04-29 | 2009-01-20 | ميرك شارب اند دوم ليمتد | Rates for the activity of the chemokine receptor of tetrahydrobranyl cycloneptil tetrahydrobredo predine |
PT1501507E (pt) * | 2002-04-29 | 2008-08-12 | Merck Sharp & Dohme | Tetrahidropiranil ciclopentil tetrahidropiridopiridinas moduladoras da actividade dos receptores de quimioquinas |
OA13338A (en) * | 2003-12-18 | 2007-04-13 | Incyte Corp | 3-cycloalkylaminopyrrolidine derivates as modulators of chemokine receptors. |
JP4845873B2 (ja) * | 2004-03-03 | 2011-12-28 | ケモセントリックス インコーポレーティッド | 二環式および架橋した窒素複素環 |
AU2005237500A1 (en) | 2004-04-28 | 2005-11-10 | Merck Sharp & Dohme Corp. | 3,3-disubstituted tetrahydropyranyl cyclopentyl amide modulators of chemokine receptor activity |
UA83142C2 (en) * | 2004-06-28 | 2008-06-10 | Инсайт Корпорейшн | 3-aminocyclopentane carboxyamidine as modulators of chemokine receptors |
WO2006004741A2 (en) * | 2004-06-28 | 2006-01-12 | Incyte Corporation | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors |
GEP20094843B (en) * | 2004-06-28 | 2009-11-25 | Incyte Corp | 3-aminocyclopentane carboxamides as modulators of chemokine receptors |
MEP1008A (xx) | 2005-12-21 | 2010-02-10 | Incyte Corp | 3-aminociklopentankarboksamidi kao modulatori receptora hemokina |
WO2010061329A1 (en) * | 2008-11-26 | 2010-06-03 | Pfizer Inc. | 3-aminocyclopentanecarboxamides as chemokine receptor modulators |
-
2009
- 2009-11-20 WO PCT/IB2009/055232 patent/WO2010061329A1/en active Application Filing
- 2009-11-20 PT PT97749394T patent/PT2370442E/pt unknown
- 2009-11-20 CA CA2743030A patent/CA2743030C/en not_active Expired - Fee Related
- 2009-11-20 UA UAA201106571A patent/UA99978C2/uk unknown
- 2009-11-20 DK DK09774939.4T patent/DK2370442T5/da active
- 2009-11-20 AP AP2011005732A patent/AP3113A/xx active
- 2009-11-20 ME MEP-2011-83A patent/ME01144B/me unknown
- 2009-11-20 GE GEAP200912239A patent/GEP20146064B/en unknown
- 2009-11-20 AU AU2009321221A patent/AU2009321221B2/en not_active Ceased
- 2009-11-20 NZ NZ592919A patent/NZ592919A/xx not_active IP Right Cessation
- 2009-11-20 RS RS20130260A patent/RS52810B9/sr unknown
- 2009-11-20 EP EP09774939.4A patent/EP2370442B9/en active Active
- 2009-11-20 SI SI200930601T patent/SI2370442T1/sl unknown
- 2009-11-20 MX MX2011005526A patent/MX2011005526A/es active IP Right Grant
- 2009-11-20 ES ES09774939T patent/ES2415430T3/es active Active
- 2009-11-20 PL PL09774939T patent/PL2370442T3/pl unknown
- 2009-11-20 JP JP2011538083A patent/JP5108153B2/ja active Active
- 2009-11-20 BR BRPI0920936-0A patent/BRPI0920936A2/pt not_active Application Discontinuation
- 2009-11-20 MY MYPI20112377 patent/MY152557A/en unknown
- 2009-11-20 EA EA201170721A patent/EA020470B1/ru not_active IP Right Cessation
- 2009-11-20 RS RS20130260D patent/RS52810B8/sr unknown
- 2009-11-20 CN CN200980147183.7A patent/CN102227429B/zh not_active Expired - Fee Related
- 2009-11-20 PE PE2011001105A patent/PE20110831A1/es active IP Right Grant
- 2009-11-20 KR KR1020117011887A patent/KR101374412B1/ko active IP Right Grant
-
2010
- 2010-06-07 US US12/795,266 patent/US8293903B2/en active Active
-
2011
- 2011-05-05 IL IL212732A patent/IL212732A/en active IP Right Grant
- 2011-05-18 TN TN2011000254A patent/TN2011000254A1/fr unknown
- 2011-05-24 CO CO11064157A patent/CO6361921A2/es active IP Right Grant
- 2011-05-24 NI NI201100102A patent/NI201100102A/es unknown
- 2011-05-25 EC EC2011011081A patent/ECSP11011081A/es unknown
- 2011-05-25 DO DO2011000154A patent/DOP2011000154A/es unknown
- 2011-05-25 CL CL2011001223A patent/CL2011001223A1/es unknown
- 2011-05-26 CR CR20110275A patent/CR20110275A/es unknown
- 2011-05-26 MA MA33895A patent/MA32834B1/fr unknown
- 2011-05-26 SV SV2011003923A patent/SV2011003923A/es unknown
- 2011-05-26 CU CU2011000121A patent/CU24022B1/es active IP Right Grant
- 2011-06-01 ZA ZA2011/04069A patent/ZA201104069B/en unknown
-
2012
- 2012-02-29 HK HK12102079.6A patent/HK1161261A1/xx not_active IP Right Cessation
- 2012-09-14 US US13/616,375 patent/US8946413B2/en active Active
-
2013
- 2013-05-08 HR HRP20130409AT patent/HRP20130409T2/hr unknown
- 2013-05-29 CY CY20131100427T patent/CY1114020T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6361921A2 (es) | 3-aminociclopentancarboxamidas | |
CO6501183A2 (es) | Piperidinas sustituidas como antagonistas de ccr3 | |
CL2011002706A1 (es) | Compuestos derivados de 4-(1,3-oxazol-2-il)-1h-indazol; composicion farmaceutica que los comprende; y sus usos en el tratamiento de enfermedades tales como epoc, autoinmunes, asma, entre otras. | |
CR20160191A (es) | Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4 | |
CO6531458A2 (es) | Nuevos compuestos de espiropiperidina | |
CR11150A (es) | Compuestos de bencimidazol | |
CU20130082A7 (es) | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr | |
ECSP12011930A (es) | Nuevos compuestos de espiropiperidina | |
CU20140072A7 (es) | Derivados de dihidro-oxazina y dihidro-pirido-oxazina | |
ECSP12012292A (es) | Ciertas amino-piridazinas, composicioines de las mismas y métodos de uso de los mismos | |
ECSP12012293A (es) | Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos | |
NI201100052A (es) | Derivados de picolinamida como inhibidores de cinasa. | |
UA107652C2 (en) | Carbazole compounds and therapeutic uses of the compounds | |
CR20130004A (es) | Derivados de tetrahidro-pirido-pirimidina | |
AR089781A1 (es) | Fluorometil-5,6-dihidro-4h-[1,3]oxazinas | |
UY37774A (es) | Compuestos 5-cianoindol sustituidos y usos de los mismos | |
AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
UY33118A (es) | Indazoles aminotiazolona sustituidos como moduladores del receptor a relacionado con estrógenos | |
CR20160465A (es) | Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il) metoxicarbonilamino-metil] benzamida (ms-275) | |
UY33323A (es) | Análogos de pirimidinilpiperidiniloxipiridinona como moduladores de gpr119 | |
CL2012000263A1 (es) | Compuestos derivados de amidas espiro ciclica, agonista b-adrenoreceptor y antagonista muscarinico; utiles en el tratamiento en enfermedades inflamatorias, tales como epoc. | |
ECSP11011473A (es) | Antagonistas de ccr3 de arilsulfonamida 2, 5- disustituída | |
CO6331308A2 (es) | Derivados de carboxamidaindazol con actividad sobre el receptor cb1 y composiciones farmaceuticas que los comprenden | |
CR11360A (es) | Benzotiazoles como moduladores del receptor de grelina | |
CL2010000253A1 (es) | Procedimiento de preparacion de ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable; y uno de los compuestos intermediarios considerados. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Application granted |